Real-world effectiveness of emicizumab prophylaxis in Korean patients with severe hemophilia A
Authors:
- Won Kee AhnWAWon Kee Ahn
- Chuhl Joo LyuCLChuhl Joo Lyu
- Jung Woo HanJHJung Woo Han
- Hugh Chul KimHKHugh Chul Kim
- Soyon KimSKSoyon Kim
- Ji Yoon KimJKJi Yoon Kim
- Ye Jee ShimYSYe Jee Shim
- Sung Eun KimSKSung Eun Kim
- Hee Jo BaekHBHee Jo Baek
- Bo Ram KimBKBo Ram Kim
- Jeong A. ParkJPJeong A. Park
- Ji Kyoung ParkJPJi Kyoung Park
Open Access
- 4 November 2026
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 266
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitorsBlood Research, 2024
- Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping reviewResearch and Practice in Thrombosis and Haemostasis, 2024
- Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyThe Lancet Haematology, 2023
- Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)Research and Practice in Thrombosis and Haemostasis, 2022
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studyThe Lancet Haematology, 2019
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Pathophysiology of hemophilic arthropathy and potential targets for therapyPharmacological Research, 2017
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia ANew England Journal of Medicine, 2016
- Haemophilias A and BThe Lancet, 2003